1-13 of 13
Trivikram Rajkhowa
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

CCRL2 Promotes Cytokine-Regulated Growth of Erythroleukemia Cells

Theodoros Karantanos, Christopher Esteb, Patric Teodorescu, Brandy Perkins, Ilias Christodoulou, Stamatia Vorri, Trivikram Rajkhowa, William Brian Dalton, Gabriel Ghiaur, Richard J. Jones
Journal: Blood
Blood (2022) 140 (Supplement 1): 5866–5867.
https://doi.org/10.1182/blood-2022-159538
Published: 2022
Journal Articles

Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor

Lauren Y. Lee, Daniela Hernandez, Trivikram Rajkhowa, Samuel C. Smith, Jayant Ranganathan Raman, Bao Nguyen, Donald Small, Mark Levis
Journal: Blood
Blood (2017) 129 (2): 257–260.
https://doi.org/10.1182/blood-2016-10-745133
Published: 2017
Includes: Supplemental data
Journal Articles

Phase I Trial of Maintenance Sorafenib after Allogeneic Hematopoietic Stem Cell Transplantation for Patients with FLT3-ITD AML

Yi-Bin Chen, MD, Li Shuli, PhD, Lane A. Andrew, MDPhD, Christine Connolly, Candice Del Rio, NP, Betsy Valles, NP, Morgan Curtis, Karen K. Ballen, MD, Corey S Cutler, MD MPH, Bimalangshu R Dey, MD, Areej El-Jawahri, MD, Amir T. Fathi, MD, Vincent T Ho, MD, Amy Joyce, NP, Steven L. McAfee, MD, Michelle A Rudek, Trivikram Rajkhowa, Sigitas Verselis, PhD, Joseph H. Antin, MD, Thomas R. Spitzer, MD, Mark Levis, MD PhD, Robert J. Soiffer, MD
Journal: Blood
Blood (2014) 124 (21): 671.
https://doi.org/10.1182/blood.V124.21.671.671
Published: 2014
Journal Articles

Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants

Allison Galanis, Hayley Ma, Trivikram Rajkhowa, Abhijit Ramachandran, Donald Small, Jorge Cortes, Mark Levis
Journal: Blood
Blood (2014) 123 (1): 94–100.
https://doi.org/10.1182/blood-2013-10-529313
Published: 2014
Includes: Supplemental data
Journal Articles

Pharmacodynamic Analysis Of The Inhibitory Potency Of The Tyrosine Kinase Inhibitor Midostaurin In Combination With Intensive Chemotherapy Including Allogeneic Hematopoietic Stem Cell Transplantation Followed By Maintenance Therapy In FLT3 -ITD Positive Acute Myeloid Leukemia In The Ongoing AMLSG 16-10 Trial

Sabine Kayser, MD, Mark Levis, MD, PhD, Carina Morlok, Andrea Kuendgen, MD, Michael Heuser, MD, Walter Fiedler, MD, Joerg Westermann, MD, Katharina Goetze, MD, Helmut R. Salih, MD, Andreas L. Petzer, MD, Frank Hartmann, MD, Heinz A. Horst, MD, Uwe M. Martens, MD, Gerald Wulf, MD, Michael Luebbert, MD, Ph.D., Dominik Wolf, MD, Richard Greil, MD, Claus-Henning Koehne, MD, Mark Ringhoffer, MD, Hartmut Kirchner, MD, Michael Pfreundschuh, MD, Brigitte Schlegelberger, MD, PhD, Patricia Erdmann, Trivikram Rajkhowa, Peter Paschka, MD, Verena I. Gaidzik, MD, Veronica Teleanu, MD, Felicitas Thol, MD, Arnold Ganser, Hartmut Doehner, MD, Konstanze Doehner, MD, Richard F. Schlenk, MD
Journal: Blood
Blood (2013) 122 (21): 1283.
https://doi.org/10.1182/blood.V122.21.1283.1283
Published: 2013
Journal Articles

Early Results Of a Phase I/II Trial Of Midostaurin (PKC412) and 5-Azacytidine (5-AZA) For Patients (Pts) With Acute Myeloid Leukemia and Myelodysplastic Syndrome

Paolo Strati, MD, Hagop M Kantarjian, MD, Aziz Nazha, MD, Gautam Borthakur, MD, Naval G. Daver, MD, Tapan M. Kadia, MD, Zeev Estrov, MD, Guillermo Garcia-Manero, MD, Trivikram Rajkhowa, Farhad Ravandi, MD, Menda Durand, MSN, RN, Mark Levis, MD, PhD, Jorge E. Cortes, MD
Journal: Blood
Blood (2013) 122 (21): 3949.
https://doi.org/10.1182/blood.V122.21.3949.3949
Published: 2013
Journal Articles

Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT -3 internal tandem duplication mutation

Clinical Trials & Observations
Farhad Ravandi, Mona Lisa Alattar, Michael R. Grunwald, Michelle A. Rudek, Trivikram Rajkhowa, Mary Ann Richie, Sherry Pierce, Naval Daver, Guillermo Garcia-Manero, Stefan Faderl, Aziz Nazha, Marina Konopleva, Gautam Borthakur, Jan Burger, Tapan Kadia, Sara Dellasala, Michael Andreeff, Jorge Cortes, Hagop Kantarjian, Mark Levis
Journal: Blood
Blood (2013) 121 (23): 4655–4662.
https://doi.org/10.1182/blood-2013-01-480228
Published: 2013
Includes: Supplemental data
Journal Articles

Crenolanib Is A Highly Potent, Selective, FLT3 TKI with Activity Against D835 Mutations

Allison Galanis, Trivikram Rajkhowa, Chaitanya Muralidhara, Abhijit Ramachandran, Mark J. Levis, MD, PhD
Journal: Blood
Blood (2012) 120 (21): 1341.
https://doi.org/10.1182/blood.V120.21.1341.1341
Published: 2012
Journal Articles

Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3/ITD AML

Amy Sexauer, Alexander Perl, Xiaochuan Yang, Michael Borowitz, Christopher Gocke, Trivikram Rajkhowa, Christian Thiede, Mark Frattini, Grant E. Nybakken, Keith Pratz, Judith Karp, B. Douglas Smith, Mark Levis
Journal: Blood
Blood (2012) 120 (20): 4205–4214.
https://doi.org/10.1182/blood-2012-01-402545
Published: 2012
Includes: Supplemental data
Journal Articles

Terminal Differentiation of FLT3/ITD AML Blasts In Patients Treated with the FLT3 Inhibitor AC220

Mark J. Levis, MD, PhD, Amy Sexauer, Trivikram Rajkhowa, Donald Small, MD, PhD, Michael J. Borowitz, MD, PhD
Journal: Blood
Blood (2010) 116 (21): 660.
https://doi.org/10.1182/blood.V116.21.660.660
Published: 2010
Journal Articles

FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML

Keith W. Pratz, Takashi Sato, Kathleen M. Murphy, Adam Stine, Trivikram Rajkhowa, Mark Levis
Journal: Blood
Blood (2010) 115 (7): 1425–1432.
https://doi.org/10.1182/blood-2009-09-242859
Published: 2010
Journal Articles

PIM: An Integral Component of FLT3 Signaling and a Potential Therapeutic Target in Acute Myeloid Leukemia.

Amir T. Fathi, Ian Swinnen, Trivikram Rajkhowa, Donald Small, Fredrik Marmsater, John E Robinson, Stefan David Gross, Matthew Martinson, Shelley Allen, Nick Kallan, Mark Levis
Journal: Blood
Blood (2009) 114 (22): 1735.
https://doi.org/10.1182/blood.V114.22.1735.1735
Published: 2009
Journal Articles

FLT3 Mutant to Wild Type Allelic Ratio and Clinical Status Are Predictive of Response to FLT3 Inhibitors in AML.

Mark Levis, Takashi Sato, Kathleen Murphy, Trivikram Rajkhowa, Keith Pratz
Journal: Blood
Blood (2009) 114 (22): 1716.
https://doi.org/10.1182/blood.V114.22.1716.1716
Published: 2009